Quantcast

Latest implantable medical devices Stories

2013-03-14 23:02:05

Number of implantable medical devices manufactured from PEEK-OPTIMA and cleared for market in the US reached 500, with more than 80 approved for market in China. Thornton-Cleveleys, UK (PRWEB) March 14, 2013 Invibio Biomaterial Solutions' innovative PEEK-OPTIMA® family of biomaterials — including the world's first implantable grade polyetherketone (PEEK) polymer — have achieved considerable regional regulatory milestones, particularly significant in the current regulatory...

2009-05-11 15:19:00

Enhanced design now features End-of-Life capability and longer life PLANO, Texas, May 11 /PRNewswire/ -- EaglePicher Medical Power, LLC, a leading supplier of batteries for implantable medical devices, today announced the introduction of its enhanced Lithium Carbon Monofluoride (Li/CFx) battery technology with end-of-life capability superior to currently available products in the market. The technology includes a proprietary new Elective Replacement Indicator (ERI) / End of Life (EOL)...

2008-10-24 09:00:26

MIV Therapeutics, Inc. (OTCBB: MIVI) (FRANKFURT: MIV) (http://www.mivtherapeutics.com), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, was featured in Cardiovascular Business News, a newsweekly concerning cardiovascular medicine. The article, titled "MIV Therapeutics CEO Discusses Future of Polymer-Free DES," can be accessed at...

2008-10-23 09:00:38

MIV Therapeutics, Inc. (OTCBB: MIVI) (FRANKFURT: MIVN) (www.mivtherapeutics.com), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, was featured on the front page of Medical Device Daily's October 22, 2008, edition. The article by Amanda Pedersen titled, "JACC publishes MIV's VESTASYNC I trial results," highlights the Journal of the American College of Cardiology's (JACC) publication of...

2008-10-21 12:00:33

MIV Therapeutics, Inc. (OTCBB: MIVI) (FRANKFURT: MIVN), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced that the Journal of the American College of Cardiology Intervention (JACC Intervention) published preliminary results from the VESTASYNC I trial. The peer-reviewed article titled "Preliminary Results of the Hydroxyapatite Non-Polymer-Based Sirolimus-Eluting Stent for the Treatment...

2008-10-21 09:00:54

MIV Therapeutics, Inc. (OTCBB: MIVT) (FRANKFURT: MIVN), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced that the Journal of the American College of Cardiology Intervention (JACC Intervention) published preliminary results from the VESTASYNC I trial. The peer-reviewed article titled "Preliminary Results of the Hydroxyapatite Non-Polymer-Based Sirolimus-Eluting Stent for the Treatment...

2008-10-09 12:00:38

MIV Therapeutics, Inc. (OTCBB:MIVI) (Frankfurt:MIV), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced today its participation at the Transcatheter Cardiovascular Therapeutics (TCT) 2008 conference. The conference will be held on October 12-17 at the Washington Convention Center in Washington, D.C. On Monday, October 13 in Room 154AB at 1:22 p.m. Eastern time, as part of the...

2008-09-18 09:00:50

MIV Therapeutics, Inc. (OTCBB: MIVI, www.mivtherapeutics.com) CEO and President, Dr. Mark Landy, will be featured on a panel at the Medical Design & Manufacturing Minneapolis Conference taking place Tuesday, October 21st through Thursday October 23rd at the Minneapolis Convention Center in Minneapolis, Minnesota. MIV is a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices. Dr. Landy will...

2008-09-15 09:00:58

MIV Therapeutics, Inc. (OTCBB: MIVI, www.mivtherapeutics.com), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, provides corporate update. In August, MIV reported continued excellent results of VESTAsync(TM), a polymer-free drug-eluting stent, at a twelve-month clinical follow up for all fifteen patients in its first-in-man (FIM) VESTASYNC I Trial. Patients remain free of any major adverse...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related